LUDA Partners, a company specialized in the digitalization of pharmacies and the intelligent connection of the pharmacy channel, has announced the opening of a new investment round aimed exclusively at professionals in the pharmaceutical sector. The minimum investment is €2,500, a format designed to strengthen the strategic link between the company and the sector driving its growth, while also giving more prominence to pharmacists, considered a fundamental pillar of the company.
The company has confirmed that professionals participating in this round will enjoy the same economic terms as the major funds currently in the shareholding structure, including Moira Capital Partners, which led the last funding round, and Hydrangea.
“Over the past few years, many pharmacists and industry professionals have expressed interest in participating in LUDA. In the last round, the success of the initiative required its expansion, reaching an investment close to €500,000 and resulting in more than 50% of shareholders being pharmacies and sector agents today. Those who have already participated in LUDA are aware of the value of their investment: for every €1 invested, it is now worth €27. With this round, from LUDA and together with Moira, we reinforce our commitment to an open innovation model, where the sector itself can play an active role in an idea that is already crossing borders. We adapt to the reality of the sector, in which cooperatives and industry allow this direct and strategic participation,” says Luis Martín Lázaro, co-founder of LUDA Partners.
The capital raised will be used to consolidate the Spanish market, accelerate international expansion—especially in Ireland and the United Kingdom—and develop new artificial intelligence solutions for pharmacies, designed to address real needs identified by the professionals themselves.
With this operation, LUDA Partners aims to accelerate its growth plan, strengthen its presence in the European pharmaceutical ecosystem, and advance technologies that solve real and current sector challenges.
From software to artificial intelligence: constant evolution
Since its founding in 2017, LUDA Partners, which already has 15% of Spanish pharmacies on board, has maintained a strong commitment to continuous innovation. The company entered the market with a clear objective: to connect pharmacies to improve patient care in the face of medication supply issues in Spain. Subsequently, LUDA evolved its technology to strengthen the pharmacy channel, turning historical competitors into strategic allies and helping them consolidate their presence in online sales.
Shortages and over-the-counter (OTC) sales
Over the past year, the company has developed an artificial intelligence and automation tool that allows pharmacies to anticipate potential shortages, plan their supply proactively, prevent stockouts, and improve patient care. In addition, LUDA is facilitating pharmacy access to online sales of over-the-counter (OTC) medicines, adapting to European regulations and strengthening an exclusive pharmacy domain, in response to a real societal demand.
LUDA is also preparing to enable pharmacies to sell on Amazon “in a simple way, respecting the Mediterranean model of the Spanish pharmacy,” as the company has advocated since its inception. According to this model, the nearest pharmacy to the patient is guaranteed to dispense the product, significantly expanding the online sales capacity through the world’s largest marketplace.
With all these initiatives, LUDA Partners aims to consolidate its position as a benchmark in technological innovation for pharmacies, combining digitalization, artificial intelligence, and strategies that benefit both industry professionals and citizens.
How to participate
Pharmacists interested in investing simply need to visit the LUDA Partners website and complete the form provided at this link.
cloud technology axon
Xcalibur Smart Mapping, recognised as the global leader in airborne...
